HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

K Reich Selected Research

Psoriasis (Pustulosis Palmaris et Plantaris)

8/2022Long-term efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis: a post hoc pooled analysis of AMAGINE-2 and -3.
2/2022Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials.
1/2022Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis.
12/2021Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study.
12/2021Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysis.
12/2021Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2.
12/2021Association of sex and systemic therapy treatment outcomes in psoriasis: a two-country, multicentre, prospective, noninterventional registry study.
10/2021A multicentre open-label study of apremilast in palmoplantar pustulosis (APLANTUS).
10/2021Complete clearance and Psoriasis Area and Severity Index response for brodalumab and ustekinumab by previous treatment history in AMAGINE-2 and AMAGINE-3.
5/2021Network meta-analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values ≤1, 2, 3 or 5 derived from a statistical conversion method.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


K Reich Research Topics

Disease

115Psoriasis (Pustulosis Palmaris et Plantaris)
08/2022 - 12/2000
10Psoriatic Arthritis
12/2021 - 02/2002
10Necrosis
12/2021 - 06/2003
8Infections
01/2022 - 04/2013
7Inflammation (Inflammations)
01/2018 - 02/2001
6Atopic Dermatitis (Atopic Eczema)
05/2022 - 12/2001
6Neoplasms (Cancer)
02/2021 - 09/2009
5Skin Diseases (Skin Disease)
01/2018 - 02/2001
5Actinic Keratosis
04/2013 - 05/2009
4Eczema
05/2022 - 03/2011
4Pruritus (Itching)
05/2022 - 03/2011
4Skin Neoplasms (Skin Cancer)
01/2022 - 04/2013
3Chronic Disease (Chronic Diseases)
12/2021 - 12/2013
3Headache (Headaches)
01/2020 - 03/2017
3Nasopharyngitis
01/2020 - 03/2017
3Hypersensitivity (Allergy)
09/2019 - 06/2000
3Dermatitis
06/2016 - 06/2004
3Melanoma (Melanoma, Malignant)
12/2015 - 09/2009
2Ankylosing Spondylitis
01/2019 - 11/2018
2Nausea
03/2018 - 03/2017
2Respiratory Tract Infections (Respiratory Tract Infection)
03/2018 - 03/2017
2Pain (Aches)
01/2018 - 03/2011
2Stroke (Strokes)
10/2015 - 04/2011
2Rheumatoid Arthritis
10/2009 - 12/2000
2Crohn Disease (Crohn's Disease)
12/2001 - 11/2001
1Behcet Syndrome (Behcet's Syndrome)
10/2021
1Oral Ulcer (Mouth Ulcer)
10/2021
1Tuberculosis (Tuberculoses)
02/2021
1Venous Thromboembolism
01/2020
1Conjunctivitis
01/2018

Drug/Important Bio-Agent (IBA)

19Monoclonal AntibodiesIBA
01/2021 - 09/2005
16secukinumabIBA
12/2021 - 12/2014
13InterleukinsIBA
12/2021 - 06/2003
13Ustekinumab (CNTO 1275)FDA Link
12/2021 - 04/2011
13Biological ProductsIBA
12/2021 - 09/2009
13Methotrexate (Mexate)FDA LinkGeneric
01/2021 - 09/2005
11Etanercept (Enbrel)FDA Link
12/2021 - 12/2013
10tildrakizumabIBA
02/2022 - 10/2015
10CytokinesIBA
01/2021 - 12/2000
9Interleukin-17 (Interleukin 17)IBA
12/2021 - 08/2016
9ixekizumabIBA
01/2021 - 07/2017
7Adalimumab (Humira)FDA Link
12/2021 - 08/2011
7FumaratesIBA
03/2021 - 06/2011
7Pharmaceutical PreparationsIBA
02/2021 - 01/2011
6Adrenal Cortex Hormones (Corticosteroids)IBA
05/2022 - 03/2011
6Infliximab (Remicade)FDA Link
12/2013 - 09/2005
6Interleukin-10 (Interleukin 10)IBA
09/2009 - 12/2000
5brodalumabIBA
08/2022 - 08/2016
5guselkumabIBA
12/2021 - 11/2018
5apremilastIBA
12/2021 - 03/2017
5Prostaglandins AIBA
11/2019 - 03/2011
5calcipotriene (calcipotriol)FDA LinkGeneric
07/2017 - 01/2009
5betamethasone-17,21-dipropionate (betamethasone dipropionate)FDA LinkGeneric
07/2017 - 01/2009
51-phenyl-3,3-dimethyltriazene (PDT)IBA
04/2013 - 05/2009
4Certolizumab PegolFDA Link
01/2021 - 07/2012
4AcidsIBA
04/2013 - 02/2010
3baricitinibIBA
05/2022 - 01/2020
3Interleukin-12 (IL 12)IBA
12/2021 - 10/2015
3Immunoglobulin A (IgA)IBA
12/2021 - 12/2014
3Interleukin-23 (Interleukin 23)IBA
01/2020 - 01/2019
3AntibodiesIBA
09/2019 - 12/2001
3omega-Chloroacetophenone (Mace)IBA
12/2015 - 04/2011
3BF-200 ALAIBA
04/2013 - 08/2010
3Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
09/2009 - 06/2004
3Messenger RNA (mRNA)IBA
12/2001 - 12/2000
3Interleukin-16 (Interleukin 16)IBA
12/2001 - 12/2000
2Phosphodiesterase 4 InhibitorsIBA
10/2021 - 03/2017
2Janus KinasesIBA
02/2021 - 05/2016
2Biological FactorsIBA
01/2021 - 01/2021
2Dimethyl FumarateIBA
10/2019 - 10/2018
2AlitretinoinFDA Link
06/2016 - 03/2011
2Ointments (Pastes)IBA
05/2014 - 06/2011
2Interleukin-8 (Interleukin 8)IBA
06/2004 - 02/2001
2RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA
06/2004 - 11/2001
2Proteins (Proteins, Gene)FDA Link
12/2001 - 12/2000
1risankizumabIBA
01/2022
1Janus Kinase 1IBA
01/2020
1mirikizumabIBA
01/2019
1Immunoglobulins (Immunoglobulin)IBA
01/2019
1Type 4 Cyclic Nucleotide PhosphodiesterasesIBA
03/2018
1Interleukin-13IBA
01/2018
1Immunosuppressive Agents (Immunosuppressants)IBA
01/2018
1Interleukin-4 (Interleukin 4)IBA
01/2018
1Interleukin-4 Receptors (Interleukin 4 Receptor)IBA
01/2018
1Cyclosporine (Ciclosporin)FDA LinkGeneric
01/2018
1dupilumabIBA
01/2018
1Betamethasone (Celestone)FDA Link
07/2017
1ElementsIBA
07/2017
1HDL LipoproteinsIBA
03/2017
1HDL CholesterolIBA
03/2017
1Triglycerides (Triacylglycerol)IBA
03/2017
1Glucose (Dextrose)FDA LinkGeneric
03/2017
1Immunologic Factors (Immunomodulators)IBA
03/2017

Therapy/Procedure

44Therapeutics
12/2021 - 12/2001
5Photochemotherapy (Photodynamic Therapy)
04/2013 - 05/2009
3Biological Therapy
02/2021 - 12/2013
3Contraindications
03/2012 - 06/2007
2Aftercare (After-Treatment)
04/2021 - 11/2018
1Subcutaneous Injections
03/2021
1Oral Administration
03/2021